#United States #New York #Securities Class Action #Wolf Haldenstein #Telix Pharmaceuticals

Telix Pharmaceuticals Class Action Alerts Shareholders

Investors who faced monetary losses from Telix Pharmaceuticals Ltd. (NASDAQ: TLX) shares are urged to reach out to Wolf Haldenstein Adler Freeman & Herz LLP. A recent securities class action has been initiated regarding the company's performance and disclosures during the defined class period from February 21, 2025, to August 28, 2025. This timeline marks critical moments for Telix, particularly concerning its pipeline of prostate cancer therapeutics.

In a statement issued on November 13, 2025, the law firm reaffirmed its commitment to ensuring investor rights and urged affected shareholders to take action before the deadline on January 9, 2026, for lead plaintiff appointment.

Allegations Against Telix Pharmaceuticals

The class action suit alleges significant breaches of the Securities Exchange Act of 1934. Key allegations include:

• - Overstatements regarding progress on therapeutic candidates for prostate cancer.
• - Misrepresentation of the quality of its supply chain and partner operations.

The rise and fall of Telix’s stock can be traced to critical events wherein executives appeared overly optimistic about the company’s pipeline. For instance, on February 20, 2025, telix held an earnings call wherein executives proclaimed major advancements that suggested the company was on a robust growth path. They noted, "We are making great progress across our therapeutic pipeline, notably in the late-stage assets..." These optimistic projections did not hold up as scrutiny over time revealed significant challenges.

Subsequently, on July 22, 2025, prior to market opening, Telix disclosed that the U.S. Securities and Exchange Commission (SEC) issued a subpoena for documents relating to its prostate cancer drug's development. Following this, news reports indicated that Telix’s shares slumped nearly 16% after receiving this negative attention—an immediate reflection of dwindling investor confidence.
As further fallout, on August 28, 2025, it was announced that the FDA issued a Complete Response Letter concerning additional data required for a renal cancer candidate. This communication sent Telix ADSs plummeting by over 16%, showcasing the impact of regulatory hurdles on share prices. Observing the subsequent slide, shares fell further within a 48-hour period, solidifying the loss of investor faith.

Why Choose Wolf Haldenstein?

Founded in 1888, Wolf Haldenstein has a long history of advocating for investor rights through complex securities litigation. With over 125 years of legal experience, the firm passionately seeks justice for investors adversely affected by misleading corporate communications. Their skilled team firmly stands by investors fighting against misrepresentation and corporate malfeasance.

If you believe you are affected by the fall of Telix Pharmaceuticals’ shares due to these misrepresentations, it is crucial to take steps promptly to secure your position in this class action. Wolf Haldenstein encourages individuals with any relevant information or who have suffered losses to get in touch with them.

Contact Information

For more information, you can reach Wolf Haldenstein at:

• - Phone: (800) 575-0735 / (212) 545-4774
• - Email: [email protected]
• - Contact Person: Gregory Stone, Director of Case and Financial Analysis

For up-to-date information, visit Wolf Haldenstein's website.

This press release may be considered Attorney Advertising in specific jurisdictions under applicable laws and ethical rules.